NCT07182227View on ClinicalTrials.gov

PS-002 for the Treatment of IgA Nephropathy in Adults

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
GENETIC

PS-002

Adeno-associated viral vector containing the human Complement Factor I (CFI) gene

Trial Locations (11)

21287

The Johns Hopkins Hospital, Baltimore

33136

University of Miami Hospital, Miami

48109

University of Michigan Hospital, Ann Arbor

M13 9WL

Manchester University NHS Foundation Trust, Manchester

Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester

LE5 4PW

Leicester General Hospital, Leicester

NG5 1PB

Nottingham University Hospitals NHS Trust, Nottingham

BS10 5NB

Southmead Hospital, Bristol

CF14 4XW

Cardiff and Vale University Health Board, Cardiff

EH16 4SA

Royal Infirmary of Edinburgh Clinical Research Facility, Edinburgh

E1 1FR

The Royal London Hospital, London

All Listed Sponsors
lead

Purespring Therapeutics Limited

INDUSTRY

NCT07182227 - PS-002 for the Treatment of IgA Nephropathy in Adults | Biotech Hunter | Biotech Hunter